292 related articles for article (PubMed ID: 26616508)
1. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Abdel-Rahman O
Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
[TBL] [Abstract][Full Text] [Related]
2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
3. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
4. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
5. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
[TBL] [Abstract][Full Text] [Related]
6. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
Bahrami A; Hesari A; Khazaei M; Hassanian SM; Ferns GA; Avan A
J Cell Physiol; 2018 Mar; 233(3):2162-2169. PubMed ID: 28407239
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
[TBL] [Abstract][Full Text] [Related]
9. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
Yaeger R; Cercek A; O'Reilly EM; Reidy DL; Kemeny N; Wolinsky T; Capanu M; Gollub MJ; Rosen N; Berger MF; Lacouture ME; Vakiani E; Saltz LB
Clin Cancer Res; 2015 Mar; 21(6):1313-20. PubMed ID: 25589621
[TBL] [Abstract][Full Text] [Related]
10. B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.
Temraz S; Alameddine R; Shamseddine A
Curr Opin Oncol; 2015 May; 27(3):276-81. PubMed ID: 25774859
[TBL] [Abstract][Full Text] [Related]
11. How should BRAF V600E-mutated colorectal cancer be treated?
Kopetz S
Clin Adv Hematol Oncol; 2018 May; 16(5):333-335. PubMed ID: 29851929
[No Abstract] [Full Text] [Related]
12. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
13. BRAF in metastatic colorectal cancer: the future starts now.
Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
[TBL] [Abstract][Full Text] [Related]
14. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Korphaisarn K; Kopetz S
Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
Miele E; Abballe L; Spinelli GP; Besharat ZM; Catanzaro G; Chiacchiarini M; Vacca A; Po A; Capalbo C; Ferretti E
BMC Cancer; 2020 Feb; 20(1):129. PubMed ID: 32066410
[TBL] [Abstract][Full Text] [Related]
18. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
[TBL] [Abstract][Full Text] [Related]
19. Metastatic colorectal cancer: current state and future directions.
Fakih MG
J Clin Oncol; 2015 Jun; 33(16):1809-24. PubMed ID: 25918280
[TBL] [Abstract][Full Text] [Related]
20. Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancer.
Carlson JJ; Ramsey SD
J Natl Cancer Inst; 2012 Dec; 104(23):1779-80. PubMed ID: 23197491
[No Abstract] [Full Text] [Related]
[Next] [New Search]
